2024
Using an AI trial screening tool to assess language as a barrier for enrollment of underrepresented minorities in cancer clinical trials.
Corvese L, Weiss C, Huie S, Zhou B, Deng Y, Gong G, Kunz P, Fischbach N. Using an AI trial screening tool to assess language as a barrier for enrollment of underrepresented minorities in cancer clinical trials. Journal Of Clinical Oncology 2024, 42: e13586-e13586. DOI: 10.1200/jco.2024.42.16_suppl.e13586.Peer-Reviewed Original ResearchClinical trialsCancer clinical trialsTrial enrollmentPercentage of patientsYale Cancer CenterClinical trial enrollmentLimitations of clinical trialsTreating providersEnrolling patientsCancer CenterUnique patientsBreast programPatientsPatient-matchedEnrollment ratesStudy-related activitiesScreening toolTrial participantsTrialsCancerOffice staffClinicEnrollmentLanguage barriersNon-English
2014
Are Amended Surgical Pathology Reports Getting to the Correct Responsible Care Provider?
Parkash V, Domfeh A, Cohen P, Fischbach N, Pronovost M, Haines GK, Gershkovich P. Are Amended Surgical Pathology Reports Getting to the Correct Responsible Care Provider? American Journal Of Clinical Pathology 2014, 142: 58-63. PMID: 24926086, DOI: 10.1309/ajcpy55evinjclgx.Peer-Reviewed Original ResearchConceptsCare providersTumor board discussionChart reviewPatient chartsPhysician chartsElectronic health record systemsPatient referralMalignant diagnosisErroneous managementSurgical pathologyHealth record systemsClinical teamOriginal diagnosisDiagnostic changesPhysiciansNew physiciansReport reviewPatientsRecord systemReferralDiagnosisEMR systemBoard discussionsDelivery systemReview
2010
Baseline (BL) radiographic characteristics and severe pulmonary hemorrhage (SPH) in bevacizumab (BV)-treated non-small cell lung cancer (NSCLC) patients (pt): Results from ARIES, an observational cohort study (OCS).
Kumar P, Fischbach N, Brahmer J, Spigel D, Beatty S, Teng S, Flick E, Sing A, Lynch T. Baseline (BL) radiographic characteristics and severe pulmonary hemorrhage (SPH) in bevacizumab (BV)-treated non-small cell lung cancer (NSCLC) patients (pt): Results from ARIES, an observational cohort study (OCS). Journal Of Clinical Oncology 2010, 28: 7619-7619. DOI: 10.1200/jco.2010.28.15_suppl.7619.Peer-Reviewed Original Research
2009
9006 Safety of bevacizumab (BV) combined with chemotherapy (CTX) in patients (pts) with non-small cell lung cancer (NSCLC): interim results from the ARIES Lung observational cohort study (OCS)
Jahanzeb M, Fischbach N, Kosty M, Kumar P, Spigel D, Wozniak A, Teng S, Wang L, Sing A, Lynch T. 9006 Safety of bevacizumab (BV) combined with chemotherapy (CTX) in patients (pts) with non-small cell lung cancer (NSCLC): interim results from the ARIES Lung observational cohort study (OCS). European Journal Of Cancer Supplements 2009, 7: 507. DOI: 10.1016/s1359-6349(09)71719-7.Peer-Reviewed Original Research